Neoplasm Malignant Clinical Trials

3 recruiting

Frequently Asked Questions

Common questions about Neoplasm Malignant clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 20 trials

Recruiting
Phase 1Phase 2

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

Lung Neoplasm Malignant
Merck Sharp & Dohme LLC190 enrolled3 locationsNCT07286149
Recruiting
Phase 2

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

Lung Neoplasm Malignant
Merck Sharp & Dohme LLC60 enrolled31 locationsNCT06788912
Recruiting

Step Count and Treatment Response in Neoadjuvant Breast Cancer

ExerciseBreast Cancer FemalesBreast Neoplasm Malignant Female+3 more
Ankara Etlik City Hospital82 enrolled2 locationsNCT07162675
Recruiting
Phase 1

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

NeoplasmsNeoplasms by SiteBrain Diseases+30 more
M.D. Anderson Cancer Center24 enrolled3 locationsNCT03911388
Recruiting
Phase 2

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors

Drug ResistanceMetastatic Solid CancersRadiotherapy+3 more
Chuangzhen Chen48 enrolled1 locationNCT07071103
Recruiting
Not Applicable

Benefit of Spectral Information in Patients Suspected for Lung Cancer

Lung Neoplasm Malignant
Copenhagen University Hospital at Herlev1,000 enrolled1 locationNCT06440616
Recruiting
Phase 2

Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer

Breast Neoplasm Malignant Female
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano152 enrolled1 locationNCT06938724
Recruiting
Not Applicable

TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography

Breast Neoplasm Malignant Primary
Norwegian University of Science and Technology250 enrolled1 locationNCT06310330
Recruiting

Metabolomics to Predict Treatment Response and Toxicities in Rectal Cancer

Rectal Neoplasm Malignant
Chang Gung Memorial Hospital250 enrolled1 locationNCT06831669
Recruiting
Phase 2

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

Endometrial Neoplasm Malignant Stage I
Fudan University104 enrolled1 locationNCT05247268
Recruiting

Preoperative vs. Pathologic Size in Breast Cancer: A Prospective Study

MastectomyBreast Neoplasm Malignant Primary
Incheon St.Mary's Hospital600 enrolled1 locationNCT06505577
Recruiting
Not Applicable

Confocal Laser Endomicroscopy VERification

Lung CancerCarcinoma, Non-Small Cell LungLung Neoplasm Malignant+1 more
Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)208 enrolled7 locationsNCT06079970
Recruiting
Not Applicable

Safety and Performance of REGENERA Breast Implant in Women Affected by Malignant Breast Lesion Treated by Lumpectomy

Mastectomy, SegmentalBreast Neoplasm Malignant Female
Tensive SRL92 enrolled3 locationsNCT05941299
Recruiting
Not Applicable

Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer

Lung Neoplasm Malignant
Ruijin Hospital20 enrolled1 locationNCT04973293
Recruiting

MONDRIAN: Multi-omics Integrative Modelling for Stereotactic Body Radiotherapy in Early-stage Non-small Cell Lung Cancer

Lung Neoplasm Malignant
European Institute of Oncology270 enrolled2 locationsNCT05974475
Recruiting
Phase 2

Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study

Neoplasm MalignantColon Cancer Stage 4
Al-Azhar University60 enrolled1 locationNCT06575127
Recruiting
Phase 1Phase 2

A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors

Neoplasm Malignant
Tasly Pharmaceutical Group Co., Ltd132 enrolled1 locationNCT06238687
Recruiting
Not Applicable

Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer

Fertility PreservationEndometrial NeoplasmsEndometrial Neoplasm Malignant+2 more
Peking University People's Hospital57 enrolled1 locationNCT05945407
Recruiting
Not Applicable

Total Mesorectal Excision(TME) With Lateral Lymph Node Dissection Versus TME After Neoadjuvant Chemo-radiotherapy

Rectal Neoplasm Malignant
Sixth Affiliated Hospital, Sun Yat-sen University250 enrolled1 locationNCT03587480
Recruiting
Not Applicable

SBRT for Breast Cancer Oligometastases

Breast Neoplasm Malignant Female
King Hussein Cancer Center50 enrolled1 locationNCT04424732